Accessibility Menu
 
PreveCeutical Medical logo

PreveCeutical Medical

(OTC) PRVCF

Current Price$0.01
Market Cap$5.69M
Since IPO (2017)-92%
5 Year-60%
1 Year-27%
1 Month-40%

PreveCeutical Medical Financials at a Glance

Market Cap

$5.69M

Revenue (TTM)

$0.00

Net Income (TTM)

$3.08M

EPS (TTM)

$-0.00

P/E Ratio

-2.49

Dividend

$0.00

Beta (Volatility)

0.17 (Low)

Price

$0.01

Volume

1,000

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.04

PRVCF News

No articles available.

PRVCF: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PreveCeutical Medical

Industry

Pharmaceuticals

CEO

Stephen van Deventer

Headquarters

Vancouver, BC V6B 0R6, CA

PRVCF Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

38%

Return on Assets

-7%

Earnings Yield

-40.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.69M

Shares Outstanding

586.81M

Volume

1.00K

Short Interest

0.00%

Avg. Volume

48.88K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$812.47K

EBITDA

$752.58K

Operating Cash Flow

$426.69K

Capital Expenditure

$1.80K

Free Cash Flow

$428.49K

Cash & ST Invst.

$59.14K

Total Debt

$4.46M

PreveCeutical Medical Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$3.61K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.69M

N/A

Market Cap/Employee

$813.16K

N/A

Employees

7

N/A

Net Income

$818.92K

-143.7%

EBITDA

$769.24K

-206.5%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Net Cash

$4.50M

-4.7%

Accounts Receivable

$18.83K

-27.3%

Inventory

$0.00

N/A

Long Term Debt

$65.19K

+5.0%

Short Term Debt

$4.54M

+7.1%

Return on Assets

-6.75%

N/A

Return on Invested Capital

38.19%

N/A

Free Cash Flow

$521.20K

-365.8%

Operating Cash Flow

$521.19K

-366.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GLABFGemina Laboratories Ltd.
$0.05+0.00%
QPTFFQuest PharmaTech Inc.
$0.01+0.00%
PPCBPropanc Biopharma, Inc.
$0.12-2.36%
HMTXFHemostemix Inc.
$0.05-9.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.13+0.08%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$75.25-0.06%
IBITiShares Bitcoin Trust
$40.55+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$86.48+0.01%

Questions About PRVCF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.